HC Wainwright & Co. Reiterates Buy on Panbela Therapeutics, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Panbela Therapeutics (NASDAQ:PBLA) and maintained a price target of $16.
July 24, 2023 | 4:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Panbela Therapeutics has received a reiterated 'Buy' rating and a maintained price target of $16 from HC Wainwright & Co.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Panbela Therapeutics. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100